Index - 2021

2021 / 2020 / 2019 / 2018



  • Other
  • Main articleH
  • Attention!LO
  • New
A
adverse effects EMA 202157-62 FDA 202157-62 authorisation 20215-7 authorisation 202157-62 blood glucose lowering drug 202157-62 diabetes 202157-62 guidelines 202157-62 myocardial infarction 202157-62 observational research 202157-62 pharmaco-epidemiological research 20215-7 prevention 20215-7 randomised research 202157-62 rosiglitazone 202157-62 vaccines 20215-7 amiodarone biotin 202195-99 thyroid disorder 202195-99 thyroid gland 202195-99 vitamin B8 202195-99 amisulpride antipsychotics 202121-28 schizophrenia 202121-28 andexanet alfa DOAC 202183-88 PCC 202183-88 antidotes 202183-88 apixaban 202183-88 dabigatran 202183-88 idarucizumab 202183-88 prothrombin complex concentrate 202183-88 rivaroxaban 202183-88 anti-inflammatory drugs corticosteroids 202163-68 covid-19 202163-68 immunosuppressive drugs 202163-68 pneumonia 202163-68 respiratory failure 202163-68 tocilizumab 202163-68 antidotes DOAC 202183-88 PCC 202183-88 andexanet alfa 202183-88 apixaban 202183-88 dabigatran 202183-88 idarucizumab 202183-88 prothrombin complex concentrate 202183-88 rivaroxaban 202183-88 antipsychotics amisulpride 202121-28 schizophrenia 202121-28 apixaban DOAC 202183-88 PCC 202183-88 andexanet alfa 202183-88 antidotes 202183-88 dabigatran 202183-88 idarucizumab 202183-88 prothrombin complex concentrate 202183-88 rivaroxaban 202183-88 arrhythmia atrial fibrillation 202117-20 medical app 202117-20 medical device 202117-20 smartwatch app 202117-20 AstraZeneca Vaxzevria® 202129-34 covid-19 202129-34 ema 202129-34 mutation 202129-34 pandemic 202129-34 vaccines 202129-34 vector vaccine 202129-34 atrial fibrillation arrhythmia 202117-20 medical app 202117-20 medical device 202117-20 smartwatch app 202117-20 authorisation EMA 202157-62 FDA 202157-62 adverse effects 20215-7 adverse effects 202157-62 blood glucose lowering drug 202157-62 diabetes 202157-62 guidelines 202157-62 myocardial infarction 202157-62 observational research 202157-62 pharmaco-epidemiological research 20215-7 prevention 20215-7 randomised research 202157-62 rosiglitazone 202157-62 vaccines 20215-7
B
biotin amiodarone 202195-99 thyroid disorder 202195-99 thyroid gland 202195-99 vitamin B8 202195-99 bivalent vaccine HPV 202147-56 carcinoma 202147-56 cervical 202147-56 human papilloma virus 202147-56 nonavalent vaccine 202147-56 quadrivalent vaccine 202147-56 vaccination programme 202147-56 blood glucose lowering drug EMA 202157-62 FDA 202157-62 adverse effects 202157-62 authorisation 202157-62 diabetes 202157-62 guidelines 202157-62 myocardial infarction 202157-62 observational research 202157-62 randomised research 202157-62 rosiglitazone 202157-62
C
carcinoma HPV 202147-56 bivalent vaccine 202147-56 cervical 202147-56 human papilloma virus 202147-56 nonavalent vaccine 202147-56 quadrivalent vaccine 202147-56 vaccination programme 202147-56 cardiovascular cardiovascular mortality 202174-77 colchicine 202174-77 coronary heart disease 202174-77 glucose 202141-46 interventions 202141-46 level 202141-46 lifestyle 202141-46 renal 202141-46 secondary prevention 202174-77 sglt-2 inhibitors 202141-46 type 2 diabetes mellitus 202141-46 cardiovascular mortality cardiovascular 202174-77 colchicine 202174-77 coronary heart disease 202174-77 secondary prevention 202174-77 cardiovascular problem LDL-cholesterol 20211-4 TIA 20211-4 cerebral infarction 20211-4 prevention 20211-4 cerebral infarction LDL-cholesterol 20211-4 TIA 20211-4 cardiovascular problem 20211-4 prevention 20211-4 cervical HPV 202147-56 bivalent vaccine 202147-56 carcinoma 202147-56 human papilloma virus 202147-56 nonavalent vaccine 202147-56 quadrivalent vaccine 202147-56 vaccination programme 202147-56 clopidogrel CYP2C19-genotyping 20219-12 PCI 20219-12 percutaneous coronary intervention 20219-12 poor metabolizers 20219-12 prasugrel 20219-12 stent 20219-12 thrombosis prophylaxis 20219-12 ticagrelor 20219-12 colchicine cardiovascular 202174-77 cardiovascular mortality 202174-77 coronary heart disease 202174-77 secondary prevention 202174-77 coronary heart disease cardiovascular 202174-77 cardiovascular mortality 202174-77 colchicine 202174-77 secondary prevention 202174-77 corticosteroids anti-inflammatory drugs 202163-68 covid-19 202163-68 covid-19 202178-82 dexamethasone 202178-82 immunosuppressive drugs 202163-68 inhaled corticosteroids 202178-82 oxygen therapy 202178-82 pneumonia 202163-68 respiratory failure 202163-68 sars-cov-2 202178-82 tocilizumab 202163-68 covid EMA 202169-73 immunocompromised 202169-73 monoclonal antibodies 202169-73 sars-cov-2 202169-73 viral reduction 202169-73 covid-19 AstraZeneca 202129-34 Vaxzevria® 202129-34 anti-inflammatory drugs 202163-68 corticosteroids 202163-68 corticosteroids 202178-82 dexamethasone 202178-82 ema 202129-34 immunosuppressive drugs 202163-68 inhaled corticosteroids 202178-82 mutation 202129-34 oxygen therapy 202178-82 pandemic 202129-34 pneumonia 202163-68 respiratory failure 202163-68 sars-cov-2 202178-82 tocilizumab 202163-68 vaccines 202129-34 vector vaccine 202129-34 CYP2C19-genotyping PCI 20219-12 clopidogrel 20219-12 percutaneous coronary intervention 20219-12 poor metabolizers 20219-12 prasugrel 20219-12 stent 20219-12 thrombosis prophylaxis 20219-12 ticagrelor 20219-12
D
dabigatran DOAC 202183-88 PCC 202183-88 andexanet alfa 202183-88 antidotes 202183-88 apixaban 202183-88 idarucizumab 202183-88 prothrombin complex concentrate 202183-88 rivaroxaban 202183-88 dexamethasone corticosteroids 202178-82 covid-19 202178-82 inhaled corticosteroids 202178-82 oxygen therapy 202178-82 sars-cov-2 202178-82 diabetes EMA 202157-62 FDA 202157-62 adverse effects 202157-62 authorisation 202157-62 blood glucose lowering drug 202157-62 guidelines 202157-62 myocardial infarction 202157-62 observational research 202157-62 randomised research 202157-62 rosiglitazone 202157-62 DOAC PCC 202183-88 andexanet alfa 202183-88 antidotes 202183-88 apixaban 202183-88 dabigatran 202183-88 idarucizumab 202183-88 prothrombin complex concentrate 202183-88 rivaroxaban 202183-88
E
egfr tyrokinase inhibitor Erlotinib 202135-40 non-small-cell lung carcinoma 202135-40 progression-free survival 202135-40 EMA FDA 202157-62 adverse effects 202157-62 authorisation 202157-62 blood glucose lowering drug 202157-62 covid 202169-73 diabetes 202157-62 guidelines 202157-62 immunocompromised 202169-73 monoclonal antibodies 202169-73 myocardial infarction 202157-62 observational research 202157-62 randomised research 202157-62 rosiglitazone 202157-62 sars-cov-2 202169-73 viral reduction 202169-73 ema AstraZeneca 202129-34 Vaxzevria® 202129-34 covid-19 202129-34 mutation 202129-34 pandemic 202129-34 vaccines 202129-34 vector vaccine 202129-34 Erlotinib egfr tyrokinase inhibitor 202135-40 non-small-cell lung carcinoma 202135-40 progression-free survival 202135-40
F
FDA EMA 202157-62 adverse effects 202157-62 authorisation 202157-62 blood glucose lowering drug 202157-62 diabetes 202157-62 guidelines 202157-62 myocardial infarction 202157-62 observational research 202157-62 randomised research 202157-62 rosiglitazone 202157-62
G
glucose cardiovascular 202141-46 interventions 202141-46 level 202141-46 lifestyle 202141-46 renal 202141-46 sglt-2 inhibitors 202141-46 type 2 diabetes mellitus 202141-46 glucose-lowering medication obesity 202189-94 overweight 202189-94 semaglutide 202189-94 type 2 diabetes mellitus 202189-94 weight loss 202189-94 guidelines EMA 202157-62 FDA 202157-62 adverse effects 202157-62 authorisation 202157-62 blood glucose lowering drug 202157-62 diabetes 202157-62 myocardial infarction 202157-62 observational research 202157-62 randomised research 202157-62 rosiglitazone 202157-62
H
HPV bivalent vaccine 202147-56 carcinoma 202147-56 cervical 202147-56 human papilloma virus 202147-56 nonavalent vaccine 202147-56 quadrivalent vaccine 202147-56 vaccination programme 202147-56 human papilloma virus HPV 202147-56 bivalent vaccine 202147-56 carcinoma 202147-56 cervical 202147-56 nonavalent vaccine 202147-56 quadrivalent vaccine 202147-56 vaccination programme 202147-56
I
idarucizumab DOAC 202183-88 PCC 202183-88 andexanet alfa 202183-88 antidotes 202183-88 apixaban 202183-88 dabigatran 202183-88 prothrombin complex concentrate 202183-88 rivaroxaban 202183-88 immunocompromised EMA 202169-73 covid 202169-73 monoclonal antibodies 202169-73 sars-cov-2 202169-73 viral reduction 202169-73 immunosuppressive drugs anti-inflammatory drugs 202163-68 corticosteroids 202163-68 covid-19 202163-68 pneumonia 202163-68 respiratory failure 202163-68 tocilizumab 202163-68 inhaled corticosteroids corticosteroids 202178-82 covid-19 202178-82 dexamethasone 202178-82 oxygen therapy 202178-82 sars-cov-2 202178-82 interventions cardiovascular 202141-46 glucose 202141-46 level 202141-46 lifestyle 202141-46 renal 202141-46 sglt-2 inhibitors 202141-46 type 2 diabetes mellitus 202141-46
L
LDL-cholesterol TIA 20211-4 cardiovascular problem 20211-4 cerebral infarction 20211-4 prevention 20211-4 level cardiovascular 202141-46 glucose 202141-46 interventions 202141-46 lifestyle 202141-46 renal 202141-46 sglt-2 inhibitors 202141-46 type 2 diabetes mellitus 202141-46 lifestyle cardiovascular 202141-46 glucose 202141-46 interventions 202141-46 level 202141-46 renal 202141-46 sglt-2 inhibitors 202141-46 type 2 diabetes mellitus 202141-46
M
medical app arrhythmia 202117-20 atrial fibrillation 202117-20 medical device 202117-20 smartwatch app 202117-20 medical device arrhythmia 202117-20 atrial fibrillation 202117-20 medical app 202117-20 smartwatch app 202117-20 monoclonal antibodies EMA 202169-73 covid 202169-73 immunocompromised 202169-73 sars-cov-2 202169-73 viral reduction 202169-73 mRNA-vaccin SARS-CoV-2 202113-16 mutation AstraZeneca 202129-34 Vaxzevria® 202129-34 covid-19 202129-34 ema 202129-34 pandemic 202129-34 vaccines 202129-34 vector vaccine 202129-34 myocardial infarction EMA 202157-62 FDA 202157-62 adverse effects 202157-62 authorisation 202157-62 blood glucose lowering drug 202157-62 diabetes 202157-62 guidelines 202157-62 observational research 202157-62 randomised research 202157-62 rosiglitazone 202157-62
N
non-small-cell lung carcinoma Erlotinib 202135-40 egfr tyrokinase inhibitor 202135-40 progression-free survival 202135-40 nonavalent vaccine HPV 202147-56 bivalent vaccine 202147-56 carcinoma 202147-56 cervical 202147-56 human papilloma virus 202147-56 quadrivalent vaccine 202147-56 vaccination programme 202147-56
O
obesity glucose-lowering medication 202189-94 overweight 202189-94 semaglutide 202189-94 type 2 diabetes mellitus 202189-94 weight loss 202189-94 observational research EMA 202157-62 FDA 202157-62 adverse effects 202157-62 authorisation 202157-62 blood glucose lowering drug 202157-62 diabetes 202157-62 guidelines 202157-62 myocardial infarction 202157-62 randomised research 202157-62 rosiglitazone 202157-62 overweight glucose-lowering medication 202189-94 obesity 202189-94 semaglutide 202189-94 type 2 diabetes mellitus 202189-94 weight loss 202189-94 oxygen therapy corticosteroids 202178-82 covid-19 202178-82 dexamethasone 202178-82 inhaled corticosteroids 202178-82 sars-cov-2 202178-82
P
pandemic AstraZeneca 202129-34 Vaxzevria® 202129-34 covid-19 202129-34 ema 202129-34 mutation 202129-34 vaccines 202129-34 vector vaccine 202129-34 PCC DOAC 202183-88 andexanet alfa 202183-88 antidotes 202183-88 apixaban 202183-88 dabigatran 202183-88 idarucizumab 202183-88 prothrombin complex concentrate 202183-88 rivaroxaban 202183-88 PCI CYP2C19-genotyping 20219-12 clopidogrel 20219-12 percutaneous coronary intervention 20219-12 poor metabolizers 20219-12 prasugrel 20219-12 stent 20219-12 thrombosis prophylaxis 20219-12 ticagrelor 20219-12 percutaneous coronary intervention CYP2C19-genotyping 20219-12 PCI 20219-12 clopidogrel 20219-12 poor metabolizers 20219-12 prasugrel 20219-12 stent 20219-12 thrombosis prophylaxis 20219-12 ticagrelor 20219-12 pharmaco-epidemiological research adverse effects 20215-7 authorisation 20215-7 prevention 20215-7 vaccines 20215-7 pneumonia anti-inflammatory drugs 202163-68 corticosteroids 202163-68 covid-19 202163-68 immunosuppressive drugs 202163-68 respiratory failure 202163-68 tocilizumab 202163-68 poor metabolizers CYP2C19-genotyping 20219-12 PCI 20219-12 clopidogrel 20219-12 percutaneous coronary intervention 20219-12 prasugrel 20219-12 stent 20219-12 thrombosis prophylaxis 20219-12 ticagrelor 20219-12 prasugrel CYP2C19-genotyping 20219-12 PCI 20219-12 clopidogrel 20219-12 percutaneous coronary intervention 20219-12 poor metabolizers 20219-12 stent 20219-12 thrombosis prophylaxis 20219-12 ticagrelor 20219-12 prevention LDL-cholesterol 20211-4 TIA 20211-4 adverse effects 20215-7 authorisation 20215-7 cardiovascular problem 20211-4 cerebral infarction 20211-4 pharmaco-epidemiological research 20215-7 vaccines 20215-7 progression-free survival Erlotinib 202135-40 egfr tyrokinase inhibitor 202135-40 non-small-cell lung carcinoma 202135-40 prothrombin complex concentrate DOAC 202183-88 PCC 202183-88 andexanet alfa 202183-88 antidotes 202183-88 apixaban 202183-88 dabigatran 202183-88 idarucizumab 202183-88 rivaroxaban 202183-88
Q
quadrivalent vaccine HPV 202147-56 bivalent vaccine 202147-56 carcinoma 202147-56 cervical 202147-56 human papilloma virus 202147-56 nonavalent vaccine 202147-56 vaccination programme 202147-56
R
randomised research EMA 202157-62 FDA 202157-62 adverse effects 202157-62 authorisation 202157-62 blood glucose lowering drug 202157-62 diabetes 202157-62 guidelines 202157-62 myocardial infarction 202157-62 observational research 202157-62 rosiglitazone 202157-62 renal cardiovascular 202141-46 glucose 202141-46 interventions 202141-46 level 202141-46 lifestyle 202141-46 sglt-2 inhibitors 202141-46 type 2 diabetes mellitus 202141-46 respiratory failure anti-inflammatory drugs 202163-68 corticosteroids 202163-68 covid-19 202163-68 immunosuppressive drugs 202163-68 pneumonia 202163-68 tocilizumab 202163-68 rivaroxaban DOAC 202183-88 PCC 202183-88 andexanet alfa 202183-88 antidotes 202183-88 apixaban 202183-88 dabigatran 202183-88 idarucizumab 202183-88 prothrombin complex concentrate 202183-88 rosiglitazone EMA 202157-62 FDA 202157-62 adverse effects 202157-62 authorisation 202157-62 blood glucose lowering drug 202157-62 diabetes 202157-62 guidelines 202157-62 myocardial infarction 202157-62 observational research 202157-62 randomised research 202157-62
S
sars-cov-2 EMA 202169-73 corticosteroids 202178-82 covid 202169-73 covid-19 202178-82 dexamethasone 202178-82 immunocompromised 202169-73 inhaled corticosteroids 202178-82 monoclonal antibodies 202169-73 oxygen therapy 202178-82 viral reduction 202169-73 SARS-CoV-2 mRNA-vaccin 202113-16 schizophrenia amisulpride 202121-28 antipsychotics 202121-28 secondary prevention cardiovascular 202174-77 cardiovascular mortality 202174-77 colchicine 202174-77 coronary heart disease 202174-77 semaglutide glucose-lowering medication 202189-94 obesity 202189-94 overweight 202189-94 type 2 diabetes mellitus 202189-94 weight loss 202189-94 sglt-2 inhibitors cardiovascular 202141-46 glucose 202141-46 interventions 202141-46 level 202141-46 lifestyle 202141-46 renal 202141-46 type 2 diabetes mellitus 202141-46 smartwatch app arrhythmia 202117-20 atrial fibrillation 202117-20 medical app 202117-20 medical device 202117-20 stent CYP2C19-genotyping 20219-12 PCI 20219-12 clopidogrel 20219-12 percutaneous coronary intervention 20219-12 poor metabolizers 20219-12 prasugrel 20219-12 thrombosis prophylaxis 20219-12 ticagrelor 20219-12
T
thrombosis prophylaxis CYP2C19-genotyping 20219-12 PCI 20219-12 clopidogrel 20219-12 percutaneous coronary intervention 20219-12 poor metabolizers 20219-12 prasugrel 20219-12 stent 20219-12 ticagrelor 20219-12 thyroid disorder amiodarone 202195-99 biotin 202195-99 thyroid gland 202195-99 vitamin B8 202195-99 thyroid gland amiodarone 202195-99 biotin 202195-99 thyroid disorder 202195-99 vitamin B8 202195-99 TIA LDL-cholesterol 20211-4 cardiovascular problem 20211-4 cerebral infarction 20211-4 prevention 20211-4 ticagrelor CYP2C19-genotyping 20219-12 PCI 20219-12 clopidogrel 20219-12 percutaneous coronary intervention 20219-12 poor metabolizers 20219-12 prasugrel 20219-12 stent 20219-12 thrombosis prophylaxis 20219-12 tocilizumab anti-inflammatory drugs 202163-68 corticosteroids 202163-68 covid-19 202163-68 immunosuppressive drugs 202163-68 pneumonia 202163-68 respiratory failure 202163-68 type 2 diabetes mellitus cardiovascular 202141-46 glucose 202141-46 glucose-lowering medication 202189-94 interventions 202141-46 level 202141-46 lifestyle 202141-46 obesity 202189-94 overweight 202189-94 renal 202141-46 semaglutide 202189-94 sglt-2 inhibitors 202141-46 weight loss 202189-94
V
vaccination programme HPV 202147-56 bivalent vaccine 202147-56 carcinoma 202147-56 cervical 202147-56 human papilloma virus 202147-56 nonavalent vaccine 202147-56 quadrivalent vaccine 202147-56 vaccines AstraZeneca 202129-34 Vaxzevria® 202129-34 adverse effects 20215-7 authorisation 20215-7 covid-19 202129-34 ema 202129-34 mutation 202129-34 pandemic 202129-34 pharmaco-epidemiological research 20215-7 prevention 20215-7 vector vaccine 202129-34 Vaxzevria® AstraZeneca 202129-34 covid-19 202129-34 ema 202129-34 mutation 202129-34 pandemic 202129-34 vaccines 202129-34 vector vaccine 202129-34 vector vaccine AstraZeneca 202129-34 Vaxzevria® 202129-34 covid-19 202129-34 ema 202129-34 mutation 202129-34 pandemic 202129-34 vaccines 202129-34 viral reduction EMA 202169-73 covid 202169-73 immunocompromised 202169-73 monoclonal antibodies 202169-73 sars-cov-2 202169-73 vitamin B8 amiodarone 202195-99 biotin 202195-99 thyroid disorder 202195-99 thyroid gland 202195-99
W
weight loss glucose-lowering medication 202189-94 obesity 202189-94 overweight 202189-94 semaglutide 202189-94 type 2 diabetes mellitus 202189-94